Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Typherix · 1 trial · 1 indication
Solicited reactions collected during the 7-day period after vaccination are pain, erythema, induration, chills, malaise, myalgia, headache, arthralgia and fatigue.
| Arm | Type | Description |
|---|---|---|
| NVGH Vi-CRM197 conjugate vaccine | EXPERIMENTAL | - |
| Vi-polysaccharide vaccine | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Typherix | BIOLOGICAL | 1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide |
| NVGH Vi-CRM197 | BIOLOGICAL | 1 dose of 0.5 mL containing 25 mcg of Vi-CRM |
Inclusion Criteria: 1. Males and females of age ≥18 to ≤40 years. 2. Individuals who, after the nature of the study has been explained to them, have given written consent according to local regulatory requirements. 3. Individuals in good health as determined by the outcome of medical history, physi...
Typherix is an investigational monoclonal antibody being developed for the prevention of typhoid fever, an infectious disease caused by Salmonella Typhi. It is currently in Phase 1 clinical development and has not been approved for use. The drug is being studied for its safety and immunogenicity in adult populations.
Typherix is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's potential as a preventive treatment for typhoid fever.
Typherix is currently in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. The Phase 1 trial has been completed, and the drug is not yet available for clinical use outside of research settings.
Typherix has one completed Phase 1 clinical trial registered under NCT01123941, titled 'Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)'. The trial enrolled 50 healthy adult volunteers in Belgium and was an active-controlled, randomized study.
Typherix is a monoclonal antibody, not a traditional vaccine. However, the completed clinical trial NCT01123941 evaluated a Vi-CRM197 vaccine against Salmonella Typhi, which may be related to the Typherix development program. The drug is being studied for its ability to prevent typhoid fever.
Typherix is a monoclonal antibody designed to target components of Salmonella Typhi, the bacterium that causes typhoid fever. By binding to specific antigens, it may help the immune system neutralize the pathogen and prevent infection. The exact molecular target has not been disclosed in available information.